Tilbage til forsiden

Kliniske retningslinjer

Head and neck cancer of unknown primary tumor - Diagnostic work-up, treatment, and follow-up

Version 1.0

Anbefalinger (centrale budskaber)

Udredning trin 1: Ambulant forundersøgelse

  1. Foretag en grundig anamnese, med fokus på relevante komorbiditeter og performancestatus, hvilket bl.a. anvendes til vurdering af patientens egnethed til kurativ behandling (D).

  2. Foretag en systematisk ØNH-undersøgelse, inkl. trans-nasal video faryngo-laryngoskopi, med evaluering af slimhinden i cavum nasi, cavum oris, pharynx og larynx (D).

  3. Anvend Narrow Band Imaging (NBI) eller tilsvarende modalitet, mhp. at øge detektionsraten af primærtumor (B).

  4. Foretag en systematisk ultralydsscanning af halsen mhp. at evaluere halsens bløddele inkl. lymfeknuder, spytkirtler og skjoldbruskkirtel. Foretag N-staging: beskriv antal, topografi og karakteristika ved metastasesuspekte lymfeknuder herunder morfologi og tegn på perinodal vækst (D).

  5. Foretag ultralydsvejledt finnålsaspiration af klinisk suspekte lymfeknuder og tumorer, mhp. cytologisk undersøgelse. Finnålsaspirat forberedes som udstrygninger på objektglas. Det anbefales, at den cytologiske analyse suppleres med HPV-DNA-analyse jf. # 20 (B).

  6. Diagnostisk strategi skal vejledes af kliniske fund inkl. billeddiagnostik og cytologi (fx. HPV-DNA i FNA indikerer primærtumor i oropharynx). Hvis primærtumor identificeres i forbindelse med den indledende ØNH-undersøgelse, fortsættes udredningen iht. relevante guidelines. Dokumentér topografi og dimensioner, vurdér operabilitet og foretag biopsi (D)

Udredning trin 2: Billeddiagnostik

  1. Foretag helkrops FDG-PET-CT mhp. at øge detektionsraten af primærtumor i eller udenfor hoved-halsregionen, evaluere omfanget af regionale lymfeknudemetastaser, samt identificere fjernmetastaser og synkron cancersygdom (B).

  2. MR-hals anbefales mhp. at øge detektionsraten af primærtumor i hoved- og halsregionen og opnå større detaljegrad af primærtumor (såfremt den identificeres) samt lymfeknudemetastaser (B).

Udredning trin 3: Plan for kirurgisk diagnostik

  1. Planlæg strategi for kirurgisk diagnostik i multidisciplinært regi, på et hoved-hals-onkologisk center, med involvering af hoved-hals-kirurg, onkolog, nuklearmediciner og patolog (D).

  2. Anvend kliniske prædiktorer for primærtumors lokalisation ved planlægningen af kirurgisk diagnostisk strategi, herunder særligt prædiktorer for HPV-associeret sygdom (HPV-DNA og p16) (B).

Udredning trin 4: Kirurgisk diagnostik

  1. Brug en trinvis tilgang til at beslutte hvilke kirurgiske procedurer der er klinisk relevante. Dette styres af klinisk information fra hvert trin (Følg Work-up step 4.1) (D).

  2. Kirurgisk diagnostik bør udføres af en hoved- og halskirurg, som kan vurdere operabilitet og udføre halsdissektion (D).

  3. Foretag videoendoskopi under generel anæstesi. Anvend narrow band imaging eller lignende modalitet for at øge detektionsraten af primærtumor. Foretag systematisk evaluering af slimhinden i cavum nasi, cavum oris, pharynx, larynx og proximale øsofagus, med særlig opmærksomhed på det lymfoide væv i naso- og oropharynx eftersom disse steder er hyppige lokalisationer for små primære tumorer. Random biopsier frarådes (C).

  4. Hvis primærtumor identificeres i forbindelse med endoskopi, fortsætter udredningen iht. relevante guidelines. Dokumentér topografi og dimensioner, vurdér operabilitet og foretag biopsi. Intraoperativ frysemikroskopi anbefales (D).

  5. Hvis primærtumor IKKE identificeres i forbindelse med endoskopi OG forudgående diagnostik har bekræftet cervikal lymfeknudemetastase med planocellulært karcinom, udføres bilateral palatin tonsillektomi (B). Hvis patienten tidligere er tonsillektomeret, undlades biopsi medmindre der findes rest-tonsilvæv (B).

  6. Hvis primærtumor IKKE identificeres i forbindelse med endoskopi OG forudgående diagnostik har bekræftet cervikal lymfeknudemetastase med planocellulært karcinom OG der påvises lymfoidt væv i nasopharynx, udføres endoskopisk vejledt biopsi herfra (C).

  7. Hvis primærtumor IKKE identificeres i forbindelse med endoskopi OG der IKKE foreligger en histolopatologisk diagnose på den/de suspekte cervikale lymfeknuder, udføres radikal excision af den mest suspekte lymfeknude mhp. at etablere en histopatologisk diagnose. I tilfælde af kliniske tegn på perinodal vækst, bør grovnålsbiopsi eller åben biopsi overvejes. Intraoperativ frysemikroskopi anbefales således at palatin tonsillektomi og halsdissektion kan foretages i samme seance, hvis indiceret. INDIKATION FOR INTRAOPERATIV HALSDISSEKTION: frysemikroskopi af suspekt lymfeknude viser planocellulært karcinom OG unilateral lymfeknudeinvolvering OG lymfeknudediameter ≤6 cm OG ingen tegn på perinodal vækst. Hvis frysemikroskopi af suspekt lymfeknude viser metastase fra andet end planocellulært karcinom, følges relevant guideline, baseret på histopatologi (D).

  8. Hvis primærtumor IKKE identificeres i forbindelse med endoskopi og bilateral palatin tonsillektomi OG histopatologisk undersøgelse af excideret cervikal lymfeknude viser planocellulært karcinom, positiv for p16 og/eller HPV-DNA, udføres tungebasis mukosektomi ved transoral robotkirurgi, såfremt patienten vurderes operabel (B). Denne procedure foretages typisk som en separat procedure.

  9. Hvis primærtumor IKKE identificeres i forbindelse med endoskopi og bilateral palatin tonsillektomi OG histopatologisk undersøgelse af excideret cervikal lymfeknude viser planocellulært karcinom, negativ for p16 og/eller HPV-DNA, overvejes tungebasis mukosektomi ved transoral robotkirurgi, såfremt patienten vurderes operabel (C). Denne procedure foretages typisk som en separat procedure.

Udredning trin 5: Cytologi og histopatologi

  1. Finnålsaspirat fra suspekte cervikale lymfeknuder bør forberedes som udstrygninger på objektglas. Objektglas skal evalueres mikroskopisk af en patolog med ekspertise i hoved- og halspatologi. Følgende bør fremgå af patologirapporten: benign, malignitetssuspekte celler, maligne tumorceller, inkonklusiv. Ved maligne tumorceller bør subtypebestemmelse anføres. HPV-DNA-analyse med PCR anbefales (B).

  2. Biopsimateriale fra suspekte primære tumorsites indsendes formalinfikseret eller ufikseret (til frysemikroskopi) mhp. histopatologisk undersøgelse ved hoved-hals patolog. Ektomi-præparater, f.eks. palatine tonsiller og tungebasis-resektater, skal orienteres og markeres af kirurgen forud for histopatologisk undersøgelse. Histopatologisk undersøgelse skal inkludere immunhistokemisk analyse, herunder p16-status. Analyse for HPV-DNA anbefales. Ektomi-præparater skal undersøges systematisk med tynde snit (max 2 mm) mhp. at identificere mikrofoci. Ved HPV-associeret cancer hvor primærtumor ikke identificeres, anbefales p16-farvning samt reevaluering af ektomi-præparaterne ved en anden patolog (D).

  3. Hvis primærtumor identificeres i ektomi-præparatet, skal der foretages en detaljeret histopatologisk beskrivelse, inkl. tumorstørrelse, type, differentieringsgrad (hvis relevant) og resektionsrande (D).

  4. Histopatologisk evaluering af exciderede cervikale lymfeknuder bør inkludere immunhistokemisk analyse med vurdering af p16-status. Ligeledes anbefales analyse for HPV-DNA. Ved halsdissektion bør evalueringen desuden indeholde: antal benigne lymfeknuder (level og total), antal metastaser (level og total), dimensioner på metastaser (OBS: intralymfatiske metastasemål), samt tilstedeværelse, udbredelse og morfologiske karakteristika af perinodal vækst (D).

  5. Hvis histopatologisk evaluering af den exciderede cervikale lymfeknude viser p16/HPV negativ ikke-keratiniserende planocellulært karcinom eller udifferentieret karcinom, bør der udføres in situ hybridisering for Epstein-Barr Virus (B).

Behandling: Kirurgi og (kemo-) strålebehandling

  1. Tilstræb tidlig planlægning af behandlingsstrategi, idet diagnostik og behandling ofte overlapper, og tid til behandlingsstart har prognostisk betydning (B). Behandling omfatter halsdissektion og/eller strålebehandling. Ved strålebehandling, foretrækkes ensidig og volumenreduceret behandling, medmindre der er bilaterale lymfeknudemetastaser eller N3-sygdom (C). Beslutning om behandlingsstrategi træffes på baggrund af multidisciplinær tumorkonference (D).

  2. Volumenreduceret strålebehandling betegner unilateral strålebehandling af halsens lymfeknuder, typisk level II-IV uden samtidig bestråling larynx og pharynx. Volumenreduceret strålebehandling kan tilbydes patienter med unilaterale cervikale metastaser OG komplet gennemført udredning iht. aktuelle guidelines, i form af billeddiagnostik og kirurgisk diagnostisk (B).

  3. Ved EN cervikal lymfeknudemetastase ≤6 cm OG komplet gennemført udredning iht. aktuelle guidelines i form af billeddiagnostik og kirurgisk diagnostik anbefales ENTEN: 1) selektiv halsdissektion level 2-4 inkl. involverede levels HVIS metastase ≤3 cm (HPV-negativ) eller ≤4 cm (HPV-positiv) OG ingen perinodal vækst; ELLER 2) volumenreduceret strålebehandling +/- kemoterapi (B). Dog bør behandlingsplanen altid baseres på MDT-konsensus (D).

  4. Ved FLERE cervikale lymfeknudemetastaser OG udelukkende unilaterale metastaser OG komplet gennemført udredning iht. aktuelle guidelines i form af billeddiagnostik og kirurgisk diagnostik anbefales følgende behandling: volumenreduceret strålebehandling +/- kemoterapi (C).

  5. Ved bilaterale cervikale lymfeknudemetastaser ELLER N3 sygdom anbefales strålebehandling +/- kemoterapi med bilateral bestråling af halsens lymfeknuder samt pharynx og larynx (B).

  6. Ved klinisk mistanke om Epstein-Barr virus-associeret nasopharyngeal primærtumor, anbefales behandling iht. guidelines for nasopharyngealt karcinom (A).

Opfølgning

  1. Responsevaluering bør gennemføres ca. 3 mdr. efter afsluttet behandling og bør omfatte PET/CT eller MR og klinisk ØNH-undersøgelse inklusiv trans-nasal video faryngolaryngoskopi og ultralydsscanning af halsen. Undersøgelsen skal fokusere på at identificere primærtumor (emerging primary), ny primær tumor (second primary), lymfeknuderecidiv, funktionelle forhold og behandlingsrelateret morbiditet (D).

  2. Opfølgning efter behandling bør foregå på et hoved-hals-onkologisk center på den afdeling, der har varetaget den endelige behandling, to uger, 2-3 mdr. og 6 + 12 + 18 + 24 + 36 + 42 + 60 mdr. efter endt behandling. Opfølgningen bør omfatte en grundig klinisk vurdering, herunder trans-nasal video faryngolaryngoskopi og ultralydsscanning af halsen (D).

  3. Ved mistanke om recidiv og/eller ny primærtumor bør der udføres PET/CT. Afhængigt af lokalisationen af det suspekte tumorområde bør der desuden udføres MR-hals og/eller CT af ansigtsskelet for at understøtte planlægning af eventuel salvage-kirurgi (D).

  4. Definition af emerging primary: samme histologiske type OG samme p16-status og/eller HPV-DNA-status som lymfeknudemetastasen ved primære diagnose OG diagnosticeret inden for fem år efter primære diagnose (C).

Rehabilitering

  1. Patienter med hoved- og halskræft af ukendt primærtumor udgør en meget heterogen gruppe. Omfanget af komplikationer og langtidseffekter er ofte tæt relateret til behandlingens type og intensitet. For en detaljeret gennemgang af mulige langtidseffekter og rehabiliteringsbehov henvises til de nationale retningslinjer for rehabilitering udstedt af Sundhedsstyrelsen (D).

Salvage

  1. Muligheder for salvage-behandling drøftes i regi af multidisciplinær tumorkonference og kan omfatte kirurgi, strålebehandling, kemoterapi og immunterapi (D).

English summary

Diagnostic work-up step 1: Office evaluation

  1. Obtain a comprehensive medical history, including an assessment of comorbidities and performance status, to evaluate the patient's suitability for curative treatment (D).

  2. Perform a systematic ENT-examination including a trans-nasal video pharyngo-laryngoscopy with systematic evaluation of all anatomical subsites in the oral cavity, nasal cavities, pharynx and larynx (D).

  3. Apply advanced visualization techniques, such as Narrow Band Imaging to increase the detection rate of a primary tumor (B).

  4. Perform a systematic neck ultrasonography to evaluate soft tissues of the neck including lymph nodes, salivary and thyroid glands. Perform N-staging by specifying the number of suspicious lymph nodes and their corresponding neck levels. Additionally, provide a detailed characterization of suspicious lymph nodes, including dimensions, topography, morphology, and signs of extranodal extension (D).

  5. Perform a fine-needle aspiration of clinically suspicious neck masses under ultrasonographic guidance. Fine-needle aspiration cytology should be prepared as smears on slides. HPV-DNA testing is recommended as part of the cytologic evaluation in accordance with #20 (B).

  6. The diagnostic strategy should be guided by clinical findings, including imaging and cytology (i.e., the presence of HPV-DNA in FNA indicates a primary tumor in the oropharynx). If assessment of the upper aerodigestive tract reveals a primary tumor, conduct diagnostic work-up according to relevant guideline. Document topography and dimensions, assess whether it is suitable for surgical intervention, and perform targeted biopsies from suspicious areas (D).

Diagnostic work-up step 2: Imaging

  1. Perform a whole-body FDG-PET-CT to increase the detection rate of a primary tumor within or outside the head and neck-region, and improve the assessment of nodal disease, and identify distant metastases and synchronous cancer (B).

  2. Neck MRI is recommended to increase the detection rate of an occult primary tumor in the head and neck region and gain more detailed information on the primary tumor (if detected) as well as nodal disease in the neck (B).

Diagnostic work-up step 3: Plan for surgical diagnostics

  1. The planning of a surgical diagnostic strategy should be guided by a multidisciplinary expert evaluation, incorporating the expertise of specialists in radiology, nuclear medicine, oncology, pathology, and head and neck surgery. The setting is a head and neck cancer center (D).

  2. The diagnostic strategy should be guided by clinical predictors of the primary tumor site, with particular emphasis on predictors of HPV-associated disease (HPV-DNA and p16) (B).

Diagnostic work-up step 4: Surgical diagnostics

  1. Use a stepwise approach, to decide which surgical procedures are clinically meaningful, guided by clinical information from each step (Follow Work-up step 4.1) (D).

  2. Diagnostic surgery should be performed by a head and neck surgeon qualified to assess operability and perform a neck dissection (D).

  3. Conduct a video-endoscopic evaluation of the upper aerodigestive tract under general anesthesia, with special emphasis on mucosal sites at risk: oral cavity, nasal cavities, nasopharynx, oropharynx, hypopharynx, larynx, and proximal esophagus. Apply advanced visualization techniques to identify potential primary sites. Special emphasis should be given to the examination of the pharyngeal lymphoid tissues, as these structures are common sites for small, often occult primary tumors. Random biopsies are not recommended (C).

  4. If endoscopic evaluation of the upper aerodigestive tract identifies a primary tumor, conduct diagnostic work-up according to relevant guideline. Document topography and dimensions and assess whether it is suitable for surgical intervention. Conduct directed biopsies from any suspicious areas. Intraoperative frozen section is recommended (D).

  5. If endoscopic evaluation of the upper aerodigestive tract FAILS to identify a primary tumor AND the cervical lymphadenopathy is confirmed to be squamous cell carcinoma, perform bilateral palatine tonsillectomy. In cases of previous palatine tonsillectomy and no signs of residual lymphoid tissue, random biopsies of the tonsillar fossa are not recommended (B).

  6. If endoscopic evaluation of the upper aerodigestive tract FAILS to identify a primary tumor, and the cervical lymphadenopathy is confirmed to be squamous cell carcinoma, perform endoscopic-guided directed biopsies of the nasopharynx IF lymphoid tissue is present in this region (C).

  7. If endoscopic evaluation of the upper aerodigestive tract FAILS to identify a primary tumor AND a histopathological diagnosis on the cervical lymphadenopathy has NOT been established, perform a complete and oncologically safe excision of the most suspicious lymph node to establish a histopathological diagnosis. In cases with clinical extranodal extension, an open biopsy or core needle biopsy should be considered. Intraoperative frozen section is recommended to allow immediate extension to neck dissection and palatine tonsillectomy if indicated. INDICATION FOR INTRAOPERATIVE NECK DISSECTION: squamous cell carcinoma is confirmed by frozen section of the suspicious lymph node in the neck AND lymphadenopathy is unilateral AND nodal dimensions ≤6 cm AND no clinical extranodal extension. If non-squamous cell carcinoma is confirmed by frozen section of the suspicious lymph node, the subsequent approach should be guided by histopathology and relevant guideline (D).

  8. If endoscopic evaluation of the upper aerodigestive tract, palatine tonsillectomy and directed biopsies FAIL to identify a primary tumor, AND the cervical lymphadenopathy is confirmed to be HPV-associated (HPV and/or p16-positive) squamous cell carcinoma, perform base of tongue mucosectomy by transoral robotic surgery, provided the patient is deemed suitable for surgery (B). This procedure is typically performed in a separate session.

  9. If endoscopic evaluation of the upper aerodigestive tract, palatine tonsillectomy and directed biopsies FAIL to identify a primary tumor, and the cervical lymphadenopathy is confirmed to be HPV-independent (HPV/p16-negative) squamous cell carcinoma, consider base of tongue mucosectomy by transoral robotic surgery, provided the patient is deemed fit suitable for surgery (C). This procedure is typically performed in a separate session.

Diagnostic work-up step 5: Cytology and histopathology

  1. Fine-needle aspiration cytology from suspicious cervical lymph nodes should be prepared as smears. Slides must be evaluated microscopically by a pathologist with expertise in head and neck pathology. Diagnostic findings should be classified as benign, cells suspicious of malignancy, malignant tumor cells, inconclusive. For malignant tumor cells, subtype determination should be stated. HPV-DNA analysis by PCR is recommended (B).

  2. Tissue specimens from suspected primary tumor sites should be submitted either formalin-fixed or unfixed (for frozen section microscopy) for histopathological examination by a head and neck pathologist. Excision specimens (e.g. palatine tonsils and tongue base resections) must be oriented and marked by the surgeon prior to histopathological assessment. Histopathological evaluation must include immunohistochemical assessment, including p16 status. Likewise, testing for HPV-DNA is recommended. Excision specimens should be systematically examined using thin slicing, with a maximum slice thickness of 2 mm, in order to identify microfoci. In cases of HPV-associated disease where a primary tumor is not identified, staining for p16 and re-evaluation of the specimens by another head and neck pathologist is recommended (D).

  3. If a primary tumor is identified in the resection specimen, a detailed histopathological description is essential, including tumor size, type, degree of differentiation (if relevant), and resection margins (D).

  4. Histopathological evaluation of excised cervical lymph nodes should include immunohistochemical assessment of p16 status. Likewise, testing for HPV-DNA is recommended. The evaluation should also include: number of benign lymph nodes and lymph node metastases (per neck levels and total number), size of metastases (intranodal size of metastases), and the presence, extent, and morphological features of extranodal extension (D).

  5. If histopathological evaluation of the excised cervical lymph node shows p16/HPV-negative non-keratinizing squamous cell carcinoma or undifferentiated carcinoma, in situ hybridization for Epstein-Barr Virus should be performed (B).

Treatment: Surgery and (chemo-) radiotherapy

  1. Aim for early treatment planning, as diagnostic evaluation and therapy often overlap, and time to treatment has prognostic significance (B). Treatment involves neck dissection and/or radiotherapy. For radiotherapy, a unilateral and volume-reduced approach is preferred, unless bilateral lymph node involvement or N3 disease is present (C). Clinical decisions regarding the treatment strategy should be based on multidisciplinary team consensus (D). Volume-reduced radiotherapy implies pharyngeal and laryngeal sparing and unilateral radiation treatment to neck levels II-IV and other involved levels. Volume-reduced treatment is feasible in cases with unilateral neck disease AND a complete diagnostic work-up according to this guideline, including imaging and diagnostic surgical procedures (B).

  1. For ONE nodal metastasis in the neck ≤6 cm AND a complete diagnostic work-up according to this guideline, including imaging and diagnostic surgical procedures, the recommended definitive treatment is EITHER: 1) unilateral selective neck dissection IF neck metastasis ≤3 cm (HPV negative) or ≤4 cm (HPV positive) AND no extranodal extension; OR 2) volume-reduced radiotherapy +/- chemotherapy (B). However, treatment strategy should always be based on MDT-consensus (D).

  2. For MULTIPLE nodal metastases in the neck AND unilateral neck involvement AND a complete diagnostic work-up according to this guideline, including imaging and diagnostic surgical procedures, the recommended definitive treatment is: volume-reduced radiotherapy +/- chemotherapy (C).

  3. For bilateral nodal metastases OR N3 disease the recommended definitive treatment is: radiotherapy +/-chemotherapy with bilateral elective neck irradiation and irradiation of the pharyngeal and laryngeal mucosa (B).

  4. In cases highly suggestive of an occult Epstein-Barr virus (EBV)-associated nasopharyngeal primary, treatment should adhere to the guideline concerning nasopharyngeal carcinoma (A).

Follow-up

  1. Response evaluation should be conducted three months after end of treatment and include PET/CT or MRI, a clinical ENT-examination including trans-nasal video pharyngo-laryngoscopy and neck ultrasonography. The assessment should focus on identifying an emerging primary tumor, second primary tumors, recurrent neck disease, functional outcomes, and treatment-related morbidity (D).

  2. Post-treatment follow-up should be conducted at a head and neck cancer center at the department responsible for the definite treatment, two weeks, 2-3 months, and 6 + 12 + 18 + 24 + 36 + 42 + 60 months post treatment. Surveillance should involve a comprehensive clinical evaluation, including trans-nasal video pharyngo-laryngoscopy with narrow-band imaging and neck ultrasonography (D).

  3. In cases of recurrence or the emergence of a primary or second primary tumor, a PET-CT scan should be conducted. Depending on the location of the suspicious tumor area, a neck MRI and/or a CT of the facial skeleton should be performed to assist in planning potential salvage surgery (D). Definition of an emerging primary: same histological type AND same p16 and/or HPV-DNA status as the nodal metastases at initial diagnosis AND diagnosis within five years of primary diagnosis (C).

Rehabilitation

  1. Patients with head and neck cancer of unknown primary represent a highly heterogeneous group. The extent of morbidity and long-term effects is often closely related to the type and intensity of treatment. For a detailed review of potential long-term effects and rehabilitation needs, refer to the national rehabilitation guidelines issued by the Danish Health Authority (D).

Salvage

  1. Salvage opportunities are discussed under multidisciplinary auspices and may include surgery, radiotherapy, chemotherapy, and immune therapy (D).


Forsæt til hele retningslinjen

Forfattere og habilitet

Steering Committee

  • Thomas Kjærgaard – Committee Chair & Last Author

  • Signe Bergliot Nielsen – First Author

  • Jesper Grau Eriksen – Lead Oncology

Working groups:

Diagnostic work-up

  • Thomas Kjærgaard

  • Signe Bergliot Nielsen

  • Christian Godballe

  • Jacob Kinggaard Lilja-Fisher

  • Nina Munk Lyhne

  • Camilla Molich Hoff

  • Edith Nielsen

  • Max Rhode

  • Anne Fog Lomholt

  • Mikkel Hjordt Holm Larsen

Pathology:

  • Stine Rosenkilde Larsen

  • Benedicte Parm Ulhøi

  • Katalin Kiss

Surgery:

  • Thomas Kjærgaard

  • Signe Bergliot Nielsen

  • Christian Godballe

  • Tejs Ehlers Klug

Oncology:

  • Jesper Grau Eriksen

  • Hanne Primdahl

  • Christian Maare

  • Niels Gyldenkerne

  • Anita Birgitte Gothelf

Surveillance & rehabilitation:

  • Thomas Kjærgaard

  • Signe Bergliot Nielsen

For detailed cooperative relationships, please refer to the declaration via the Danish Medicines Agency's website.


Har du en kommentar til retningslinjen?

Her har du mulighed for at kontakte Sundhedsvæsenets Kvalitetsinstitut, hvis du har en kommentar til retningslinjen. Ved behov vil instituttet videreformidle til forfatterne af retningslinjen.

Vi gør opmærksom på, at din kommentar ikke må indeholde personfølsomme oplysninger. Vi behandler ikke henvendelser, der vedrører konkrete sygdomsforløb.

(Alle felter skal udfyldes).